Coverage of our peer-reviewed research in the healthcare and mainstream press.
An article from Health Data Management, “Why Implementing EHR Systems Still Is Fraught With Risk,” described research from the most recent issue of The American Journal of Managed Care® (AJMC®). The AJMC® study “Assessing Electronic Health Record Implementation Challenges Using Item Response Theory,” identified barriers to the successful implementation of electronic health records, which included obtaining physician cooperation.
An article by Health IT Analytics reported on the findings from an AJMC® study that explored patterns of referral from patient-centered medical homes (PCMHs). The study, “Referrals and the PCMH: How Well Do We Know Our Neighborhood?” found that chronic disease diagnoses increase the likelihood of referral to specialists and that “resident physicians placed more referrals per patient than their faculty counterparts.”
Samsung’s Insights blog cited an AJMC® study on the medical cost savings resulting from improved medication adherence. The blog article, “Digital Health Tech Takes Off in Clinical Trials and Pharmaceuticals,” discussed how digital health tools like wearable medical devices can help assess medication adherence in patients.
“The American Journal of Managed Care® takes on telemedicine,” declared Politico’s Morning eHealth newsletter in its “What We’re Clicking On” section. It was referring to “Telemedicine: The Cost-Effective Future of Healthcare,” a recent article by AJMC® contributor John Rehm, the community manager for Nursing@Georgetown.
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More